促销时间表 Anebulo Pharmaceuticals, Inc.
先进的时间表
简单图表
关于公司
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.
| EBITDA |
-0.000173 |
| EV/EBITDA |
16.29 |
| IPO date |
2021-05-07 |
| ISIN |
US0345691036 |
| Industry |
Biotechnology |
| P/BV |
6.71 |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.anebulo.com
|
| Цена ао |
2.6 |
| Число акций ао |
0.02507 млрд |
| 每日价格变化: |
+4.94% (1.62) |
| 每周价格变化: |
+71.72% (0.99) |
| 每月价格变化: |
+18.88% (1.43) |
| 3个月内价格变化: |
-17.07% (2.05) |
| 六个月内的价格变化: |
-31.73% (2.49) |
| 每年价格变化: |
-29.75% (2.42) |
| 3年内价格变化: |
-74.63% (6.7) |
| 5年内价格变化: |
0% (1.7) |
| 10年价格变化: |
0% (1.7) |
| 年初以来价格变化: |
+4.94% (1.62) |
|
|
低估
| 姓名 |
意义 |
年级 |
| P/S |
0 |
0 |
| P/BV |
18.96 |
1 |
| P/E |
0 |
0 |
| EV/EBITDA |
-8.6 |
0 |
| 全部的: |
|
2.38 |
|
效率
| 姓名 |
意义 |
年级 |
| ROA, % |
-104.19 |
0 |
| ROE, % |
-113.8 |
0 |
| 全部的: |
|
0 |
|
|
|
股息
| 姓名 |
意义 |
年级 |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| 全部的: |
|
0 |
|
责任
| 姓名 |
意义 |
年级 |
| Debt/EBITDA |
0 |
10 |
| 全部的: |
|
10 |
|
成长冲动
| 姓名 |
意义 |
年级 |
| 盈利能力 Revenue, % |
0 |
0 |
| 盈利能力 Ebitda, % |
123.62 |
10 |
| 盈利能力 EPS, % |
-75.49 |
0 |
| 全部的: |
|
3.6 |
|
| 导师 |
职称 |
支付 |
出生年份 |
| Dr. Joseph F. Lawler M.D., Ph.D. |
Founder & Chairman |
11k |
1972 (53 年) |
| Dr. Kenneth C. Cundy Ph.D. |
Chief Scientific Officer |
425.15k |
1959 (66 年) |
| Mr. Richard Anthony Cunningham |
CEO & Director |
N/A |
1971 (54 年) |
| Mr. Daniel V. George |
Principal Accounting Officer, Acting CFO & Secretary |
N/A |
1970 (55 年) |
